Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

对HER2低表达乳腺癌进行IHC检测，旨在评估观察者间的一致性，并分析其与数字成像的相关性。随着乳腺癌HER2三分类新时代的到来，HER2精准检测的重要性日益显著。而病理学家对HER2 ...

*仅供医学专业人士阅读参考研究深入探讨了IHC评分与mRNA表达在HER2低表达乳腺癌中的一致性，为精准诊断提供新视角。众所周知，针对人表皮生长因子受体2（HER2）的靶向治疗显著改善了HER2阳性乳腺癌患者的预后[1]，然而在缺乏该基因改变的患者中 ...

Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma—the most common ...

Oxford BioTherapeutics (OBT) has lined up another big pharma partner for its drug discovery platform, agreeing to work with ...

Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma-the most common type of malignant brain tumour in children-and potentially sparing young ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications Agilent Technologies Inc. (NYSE: A) today ...

PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide ...